40. Pulmonary Arterial Hypertension Flashcards
Drug list that can cause pulmonary arterial HTN
Cocaine
Fenfluramine
Methamphetamine/amphetamine
SSRI use during pregnancy (increase risk of persistent pulmonary hypertension of a newborn (PPHN))
Weight-loss drugs (diethylpropion, phendimetrazine, phentermine)
Pulmonary HTN is characterized by mPAP ≥____ (normal range is ___)
≥25mmHg
Normal range 8-20 mmHg
PAH stems from an imbalance in vasoconstrictor and vasodilator substances. Vasoconstrictor substances (e.g. ____) are increased and vasodilating substances (e.g. ____) are decreased
vasoconstrictor = endotheline-1, TXA2
Vasodilator = prostacyclins
____ is the most common cause of death in pts who have PAH
HF
S/sx of PAH
Fatigue, dyspnea
Others: chest pain syncope edema, tachycardia and/or Raynaud’s phenomenon
T/F: There is no cure for PAH but there are treatment options and in some cases, a lung or heart transplant may be an option for younger patients
True
Non-drug treatments for PAH
Sodium restriction (<2.4 grams/day)
Avoid meds that increase sodium/water retention (NSAIDs)
Influenza and pneumococcal vaccines recommended
____ is performed to confirm the diagnosis of PAH
Right heart catheterization
During a right heart catheterization, what meds are administered for vasoreactivity testing?
short-acting vasodilators (e.g. inhaled nitric oxide, IV epoprostenol, IV adenosine)
What makes someone a responder during vasoreactivity testing? What treatment do you recommend for responders?
If mPAP falls by at least 10mmHg to an absolute value <40mmHg
Treatment: oral CCB
What are common CCBs used in responders?
Long-acting nifedipine, diltiazem, and amlodipine
Verapamil is NOT recommended d/t more pronounced negative inotropic effects compared to diltiazem
What are treatment options for non-responders or responders who failed CCBs?
Prostacyclin analogues and receptor agonists, endothelin receptor antagonists (ERAs), PDE-5i, and/or soluble guanylate cyclase (sGC) stimulator
Parenteral prostacyclin analogues, specifically ___, have shown to decrease mortality
IV epoprostenol
Supportive therapies for PAH may include ___ (for volume overload) and ___ (to improve cardiac output or control HR in Afib)
Loop diuretics
Diogxin
T/F: PAH leads to a higher risk of bleeding
False - leads to a pro-thrombic state and increased risk of blood clots
What is the preferred anticoagulation if needed in PAH pts?
Warfarin
MOA of prostacycline analogues
Potent vasodilators and inhibitors of platelet aggregation
Which prostacyclin analogues can be administered by continuous IV at home using an ambulatory infusion pump?
Epoprostenol and treprostinil
Treprostrinil (Remodulin) starting dose
1.25ng/kg/min, titrate
Epoprostenol (Flolan) starting dose
2ng/kg/min, titrate
CI with epoprostenol
HF with decreased LVEJ
CI with treprostinil (oral)
severe hepatic impairment (Child-Pugh C)
Warnings for prostacyclin analogues
Vasodilation reactions (hypotension, flushing, HA, dizziness)
Rebound pulmonary HTN (with interruption or large decreases in dose, can be fatal)
Chronic IV infusions: sepsis and bloostreen infections
Treprostinil (Orenitram): PO ghost shell, can lodge in diverticulum